Drug Trial Radar · NCT07923630
Validation & Intervention Testing for Aging, Longevity and Healthspan
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Dec 2030
Study completion Feb 2031
Sponsor
- Lead sponsor
- The University of Texas Health Science Center at San AntonioAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Department of Health and Human Services
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study aims to address the gap between lifespan and healthspan (years of life free of age-related diseases and disabilities) by testing whether 2 approved U.S Food and Drug Administration (FDA) medications, dapagliflozin and semaglutide, can help people stay healthier as they age and delay the age-related functional decline. The study will test these medications over 36 months of treatment plus 6 months of observational follow up to see if they can safely maintain health and function during aging and eventually support their use for extending healthspan. This study is being done because there are limited ways to slow down the age-related health and functional decline, and few reliable ways to measure early changes in healthspan in humans. The 2 study drugs have shown promising results in laboratory and early human studies, but more evidence is needed.
Conditions
- Aging
- Functional Decline
Interventions
Dapagliflozin 10Mg Oral TabletDrug
Participants will take one dapagliflozin plus one placebo pill daily for 36 months
Semaglutide oralDrug
Participants will start taking a 1.5 mg semaglutide pill, titrated to 4 mg as tolerated, plus one placebo pill per day for 36 months.
PlaceboOther
Participants will take two placebo pills daily for 36 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Continuous Short Physical Performance Battery SPPBTime frame: Baseline to end of study (approximately 36 months)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Texas Diabetes Institute
San Antonio, Texas
San Antonio Food Bank
San Antonio, Texas
Barshop Institute Mobile Research Clinic
San Antonio, Texas
Sam and Ann Barshop Institute for Longevity & Aging Studies
San Antonio, Texas
South Texas Veterans Health Care System
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.